Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel Journal Article
| Authors: | Zanwar, S.; Sidana, S.; Shune, L.; Puglianini, O. C.; Pasvolsky, O.; Gonzalez, R.; Dima, D.; Afrough, A.; Kaur, G.; Davis, J. A.; Herr, M.; Hashmi, H.; Forsberg, P.; Sborov, D.; Anderson, L. D. Jr; McGuirk, J. P.; Wagner, C.; Lieberman-Cribbin, A.; Rossi, A.; Freeman, C. L.; Locke, F. L.; Richard, S.; Khouri, J.; Lin, Y.; Patel, K. K.; Kumar, S. K.; Hansen, D. K. |
| Article Title: | Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel |
| Abstract: | Idecabtagene vicleucel (Ide-cel) has demonstrated excellent efficacy and durable responses in patients with relapsed/refractory multiple myeloma (RRMM). However, the outcomes with ide-cel in patients with extramedullary disease (EMD) remain incompletely characterized. We included patients with RRMM treated with ide-cel between May 2021 and April 2023 across 11 US academic institutions. Visceral or soft tissue lesions non-contiguous from bone was classified as EMD. Time-to-event analyses were performed from date of ide-cel infusion. Among 351 patients, 84 (24%) had EMD prior to infusion. The median follow-up from ide-cel infusion was 18.2 months (95% CI: 17-19.3). The day 90 overall response rates (ORR) were 52% vs. 82% for the EMD and non-EMD cohorts, respectively (p < 0.001). The median progression-free survival (PFS) was 5.3 months (95% CI: 4.1–6.9) for the EMD cohort vs. 11.1 months (95% CI: 9.2–12.6; p < 0.0001) for the non-EMD cohort. In a multivariable analysis, EMD was an independent predictor of inferior PFS [hazard ratio 1.5 (1.1–2.2), p = 0.02]. The median overall survival was 14.8 months [95% CI: 9-Not reached (NR)] vs. 26.9 months (26.3 vs. NR, p = 0.006) for the EMD and non-EMD cohorts, respectively. Extramedullary disease represents an independent predictor of inferior day 90 ORR and PFS among patients treated with ide-cel. © The Author(s) 2024. |
| Keywords: | adult; cancer survival; treatment outcome; treatment response; aged; aged, 80 and over; middle aged; retrospective studies; major clinical study; overall survival; clinical trial; cancer recurrence; united states; outcome assessment; cancer immunotherapy; progression free survival; multiple myeloma; radiation; cohort analysis; continuous infusion; retrospective study; immunotherapy; multicenter study; chimeric antigen receptor; drug therapy; adoptive immunotherapy; immunotherapy, adoptive; biological product; biological products; hematologic disease; progression-free survival; adverse event; procedures; survival prediction; cancer prognosis; Common Terminology Criteria for Adverse Events; tissue extract; refractory disease; tissue extracts; very elderly; humans; human; male; female; article; soft tissue injury; receptors, chimeric antigen; idecabtagene vicleucel; bcma car-t; ide-cel; relapsed/refractory myeloma; extramedullary multiple myeloma |
| Journal Title: | Journal of Hematology & Oncology |
| Volume: | 17 |
| ISSN: | 1756-8722 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2024-06-06 |
| Start Page: | 42 |
| Language: | English |
| DOI: | 10.1186/s13045-024-01555-4 |
| PUBMED: | 38845015 |
| PROVIDER: | scopus |
| PMCID: | PMC11157748 |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
